A team of researchers report that by manipulating TAK1, a signaling protein that plays an important role in development of the immune system, they can slow down disease progression and improve muscle function in Duchenne muscular dystrophy (DMD).
DMD, caused by mutations in dystrophin gene, is an inheritable neuromuscular disorder that occurs in one out of 3,600 male births. DMD patients undergo severe muscle wasting, inability to walk and eventually death in their early thirties due to respiratory failure. The disease is marked by an inflammatory response and death of muscle fibers. Eventually, the muscle fibers are replaced with fat and fibrotic tissue that causes severe muscle weakness.
“Our results suggest that TAK1 (transforming growth factor β-activated kinase1) is a regulator of skeletal muscle mass. By specifically targeting this protein, we can suppress the death of muscle fibers, known as myonecrosis, and slow down disease progression in DMD,” said the senior author, whose results were published in JCI Insight. “Our research shows that activating TAK1 can stimulate myofiber growth in a model of DMD, with no negative impact on muscle health.”
In a previous breakthrough, the team uncovered a surprising fact: TAK1 is essential for maintaining skeletal muscle mass and that activating TAK1 beyond normal levels can enhance skeletal muscle growth.
For this research, the team designed experiments to reduce or augment the levels of TAK1 protein in skeletal muscle at different stages of disease progression.
“Our experiments demonstrate that depletion of TAK1 activity during peak necrotic phase followed by re-introduction of TAK1 at post-necrotic phase leads to substantial improvement in muscle pathology,” said the lead author.
The current standard of care for DMD is focused on reducing inflammation with corticosteroids, which modestly reduces disease progression, but has serious side effects.
“Accumulating evidence suggests that regulation of immune response, autophagy, and metabolism along with gene correction therapy can be promising approaches to slow down disease progression in DMD patients,” said the author.
https://insight.jci.org/articles/view/164768
http://sciencemission.com/site/index.php?page=news&type=view&id=publications%2Ftargeted-regulation-of&filter=22
Slowing down muscular dystrophy
- 810 views
- Added
Edited
Latest News
Role of fat in rare neurolo…
By newseditor
Posted 23 Apr
How protein synthesis in de…
By newseditor
Posted 22 Apr
Atlas of mRNA variants in d…
By newseditor
Posted 22 Apr
Mapping microbiome in metas…
By newseditor
Posted 22 Apr
Full-length mRNA packaged i…
By newseditor
Posted 22 Apr
Other Top Stories
MicroRNA controls angiogenic switch in cancer
Read more
Breast cancer tumor growth is dependent on lipid availability
Read more
How tumors survive detachment during metastasis
Read more
A new mechanism of resistance to chemotherapy
Read more
Role of P53 in chemotherapy resistance
Read more
Protocols
A programmable targeted pro…
By newseditor
Posted 23 Apr
MemPrep, a new technology f…
By newseditor
Posted 08 Apr
A tangible method to assess…
By newseditor
Posted 08 Apr
Stem cell-derived vessels-o…
By newseditor
Posted 06 Apr
Single-cell biclustering fo…
By newseditor
Posted 01 Apr
Publications
Structure of antiviral drug…
By newseditor
Posted 23 Apr
Type-I-interferon-responsiv…
By newseditor
Posted 23 Apr
Selenium, diabetes, and the…
By newseditor
Posted 23 Apr
Long-term neuropsychologica…
By newseditor
Posted 23 Apr
Neuronal activity rapidly r…
By newseditor
Posted 22 Apr
Presentations
Hydrogels in Drug Delivery
By newseditor
Posted 12 Apr
Lipids
By newseditor
Posted 31 Dec
Cell biology of carbohydrat…
By newseditor
Posted 29 Nov
RNA interference (RNAi)
By newseditor
Posted 23 Oct
RNA structure and functions
By newseditor
Posted 19 Oct
Posters
A chemical biology/modular…
By newseditor
Posted 22 Aug
Single-molecule covalent ma…
By newseditor
Posted 04 Jul
ASCO-2020-HEALTH SERVICES R…
By newseditor
Posted 23 Mar
ASCO-2020-HEAD AND NECK CANCER
By newseditor
Posted 23 Mar
ASCO-2020-GENITOURINARY CAN…
By newseditor
Posted 23 Mar